Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Myeloid, Chronic-Phase 2Philadelphia Chromosome 1Neoplasm, Residual 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1Leukemia, Biphenotypic, Acute 1

Interventions

Imatinib Mesylate 14Dasatinib 5nilotinib 4bosutinib 4Cyclophosphamide 4fludarabine 3Vincristine 3Methotrexate 3Dexamethasone 3Cytarabine 3peginterferon alfa-2a 2fludarabine phosphate 2asciminib 2Prednisone 2Daunorubicin 2Azacitidine 2Acetaminophen 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2venetoclax 1thymoglobulin 1ponatinib 1olverembatinib 1flumatinib 1blinatumomab 1Whole-Body Irradiation 1Tyrosine Kinase Inhibitors 1Tacrolimus 1Rituximab 1Prednisolone 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Philadelphia Chromosome × flumatinib × Other hematologic neoplasm × Clear all
NCT05433532 2024-04-25

Study of Azacitidine,Venetoclax,and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients

The First Affiliated Hospital of Soochow University

Phase 2 Completed
20 enrolled
LymphoidMyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡